Alnylam Presents 30-Month Results from ILLUMINATE-B Phase 3 Study of OXLUMO® (lumasiran) at the Pediatric Academic Societies (PAS) 2023 Meeting

Alnylam Presents 30-Month Results from ILLUMINATE-B Phase 3 Study of OXLUMO® (lumasiran) at the Pediatric Academic Societies (PAS) 2023 Meeting

New 30-month results from the ILLUMINATE-B Phase 3 study of lumasiran in pediatric patients with primary hyperoxaluria type 1 (PH1) shared at the Pediatric Academic Societies (PAS) 2023 Meeting.

Michael, et al. “Efficacy and Safety of Lumasiran for Infants and Young Children with Primary Hyperoxaluria Type 1: 30-Month Analysis of the Phase 3 ILLUMINATE-B Trial”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.